Diphenidine
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
JSmol) | |
Melting point | 210 °C (410 °F) |
| |
|
Diphenidine (1,2-DEP, DPD, DND) is a
Electrophysiological analysis demonstrates that the amplitude of NMDA-mediated fEPSPs are reduced by diphenidine and ketamine to a similar extent, with diphenidine displaying a slower onset of antagonism.[7] The two enantiomers of diphenidine differ greatly in their ability to block the NMDA receptor, with the more potent (S)-enantiomer possessing affinity forty times higher than the (R)-enantiomer.[6] Since diphenidine's introduction in 2013 vendors have stated the drug "acts on dopamine transport" yet no data concerning the action of diphenidine on the dopamine transporter was published until 2016.[2] Diphenidine's highest affinity is for the NMDA receptor, but it does display submicromolar affinity for the σ1 receptor, σ2 receptor and dopamine transporter.[12][13]
Since 2014 there have been several published reports of diphenidine being sold in combination with other research chemicals, particularly synthetic cannabinoids and stimulants in Japanese
In Canada, MT-45 and its analogues were made Schedule I controlled substances, which includes DPD in its structural group.[19] Possession without legal authority can result in maximum seven years imprisonment. Further, Health Canada amended the Food and Drug Regulations in May, 2016 to classify explicitly DPD as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.
See also
References
- ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
- ^ PMID 24678061.
- PMID 26811026.
- S2CID 5962038.
- ^ EP 0346791, Gray NM, Cheng BK, "1,2-diarylethylamines for treatment of neurotoxic injury", issued 6 April 1994, assigned to G.D. Searle, LLC
- ^ PMID 19345586.
- ^ (PDF) from the original on 2020-03-07. Retrieved 2019-12-10.
- PMID 10373688.
- PMID 7504360.
- PMID 14188779.
- S2CID 15610561.
- PMID 27314670.
- PMID 29642450.
- ^ S2CID 25995354.
- ^ S2CID 11884184.
- PMID 26257833.
- S2CID 44007379.
- PMID 26162997.
- ^ Arsenault D (1 June 2016). "Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18)". Canada Gazette. 150 (11). Archived from the original on 2017-12-02. Retrieved 2016-11-17.